0849 GMT - Roche is well positioned for growth in the medium-term on expedited obesity-drug ambitions, Baader Helvea analyst Abhishek Raval says in a note. The Swiss pharmaceutical company recently acquired a mid-stage weight-loss drug candidate from Danish biotech Zealand Pharma. The company also has a diversified portfolio of disease areas, Raval notes. "With significant manufacturing and commercial might...the Swiss giant could become a serious contender in the obesity market," he says. Historically, Roche has usually been the market-leader in many of the disease areas it targets, the analyst says. Any progress in Roche's obesity pipeline could fuel the already solid share-price performance in recent months, he adds. Shares fall 0.9% to 302.90 Swiss francs. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
March 26, 2025 04:49 ET (08:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.